Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
In conclusion, modified b iweekly TPEx is of comparable efficacy with conventional TPEx and represents a well-tolerated regimen in R/M SCCHN patients. Further evaluation of this protocol in prospective clinical trials is warranted.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Acne | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Docetaxel | Erbitux | Head and Neck Cancer | HNSCC | Laryngeal Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Taxotere | Toxicology